According to a study, a novel medication called enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may promote clinical action against cancer across the body.
Researchers have described prostate cancer cell dynamics at a single-cell resolution across the whole course of the disease, from the first stages to the point of androgen independence, where the tumour stops responding to hormone restriction therapy.
From the onset of the disease through the point of androgen independence, where the tumour no longer responds to hormone restriction therapy, researchers have described prostate cancer cell dynamics at a single-cell resolution over the course of the disease.
Washington [US], September 15 (ANI): For more than a decade, drugs like enzalutamide, which prevent male hormones from activating the androgen receptor, have been used to treat metastatic prostate cancer. While these treatments are generally effective, they can eventually stop working, but t